New Report Focuses on 23 Key Companies In Cancer Therapeutics

A new report from Kalorama Information ( takes a look at cancer therapeutics, with a particular focus on 23 companies.

Despite advances in cancer treatment, cancer continues to affect about 18.1 million people annually, generating a significant loss of life, financial burden and overall strain on the health industry.  Worldwide between 35 and 40 million people are living with cancer and nearly 10 million people lose the battle annually.  The most common cancers affecting the world population include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patients in underdeveloped countries.

The demand for more effective and tolerable cancer treatments has led to the development of novel therapeutic agents that specifically target the malignant cells. Today, advanced precision cancer therapies are available, and more are being developed each year.  Although there are some older precision therapies on the market, the industry is now expanding the use of these treatments to better treat cancer victims.  Precision treatments are less invasive and less damaging to the body, and they promise improved outcomes in many cases.

Kalorama Information has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market.  Precision Cancer Therapeutics, 2022 focuses on the expanding area of precision cancer therapies and includes current products available and discusses some of the most exciting developments in progress. 

This report covers precision cancer therapies that do at least one of the following:

  • Block or turn off chemical signals that tell the cancer cell to grow and divide
  • Change proteins within the cancer cells so the cells die
  • Stop making new blood vessels to feed the cancer cells
  • Trigger the immune system to kill the cancer cells
  • Carry toxins to the cancer cells to kill them, but not normal cells

The use of monoclonal antibodies in cancer therapy is currently the subject of intense investigation. Monoclonal antibodies specifically bind with target antigens and could, therefore, be used in several ways to treat cancer. Antibodies can be used to deliver a cytotoxic drug preferentially to the cancer cell and, thus, minimize drug interactions with normal cells. Similarly, antibodies can be used to direct other cytotoxic cells, such as macrophages and T cells, to tumor cells lurking in the body. Antibodies can be attached to a radioactive label and injected into a patient to screen for recurrence of tumor growth. Antibodies can also be directed against cells that support tumor growth.

In Kalorama’s report the focus is on these 23 companies that have a large presence in the cancer therapeutic market and can be considered specialists and/or innovators.

The list includes:

  • AbbVie
  • Astellas Pharma U.S., Inc
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly & Company
  • EMD Serono, Inc. (Merck KgaA)
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sanofi/Genzyme
  • Seagen Inc.
  • Takeda